Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.
Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jäger D, Büchler M, Bruckner T, Siewert J, Ott K. Blank S, et al. Among authors: stange a. Gastric Cancer. 2015 Apr;18(2):314-25. doi: 10.1007/s10120-014-0367-x. Epub 2014 Apr 11. Gastric Cancer. 2015. PMID: 24722800 Free article.
A reliable risk score for stage IV esophagogastric cancer.
Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Bläker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jäger D, Büchler M, Siewert JR, Ott K. Blank S, et al. Among authors: stange a. Eur J Surg Oncol. 2013 Aug;39(8):823-30. doi: 10.1016/j.ejso.2013.01.005. Epub 2013 Jan 31. Eur J Surg Oncol. 2013. PMID: 23375470
Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger D, Büchler M, Siewert JR, Lordick F. Ott K, et al. Among authors: stange a. Langenbecks Arch Surg. 2013 Feb;398(2):239-49. doi: 10.1007/s00423-012-1039-0. Epub 2012 Dec 27. Langenbecks Arch Surg. 2013. PMID: 23269519 Free article.
Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sisic L, Schmidt T, Lordick F, Jäger D, Grenacher L, Bruckner T, Büchler MW, Ott K. Springfeld C, et al. Among authors: stange a. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S905-14. doi: 10.1245/s10434-015-4617-x. Epub 2015 May 22. Ann Surg Oncol. 2015. PMID: 26001861 Free article.
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jäger D, Münter MW. Lorenzen S, et al. Among authors: stange a. BMC Cancer. 2011 Jun 24;11:266. doi: 10.1186/1471-2407-11-266. BMC Cancer. 2011. PMID: 21702914 Free PMC article.
A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jäger D. Berger AK, et al. Among authors: stange a. BMC Cancer. 2012 Mar 22;12:108. doi: 10.1186/1471-2407-12-108. BMC Cancer. 2012. PMID: 22439666 Free PMC article. Clinical Trial.
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
Berger AK, Lücke S, Abel U, Haag GM, Grüllich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, Lordick F, Haberkorn U, Jäger D. Berger AK, et al. Among authors: stange a. Br J Cancer. 2018 Jul;119(2):170-175. doi: 10.1038/s41416-018-0152-4. Epub 2018 Jul 2. Br J Cancer. 2018. PMID: 29961759 Free PMC article. Clinical Trial.
Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555).
Rahbari NN, Lordick F, Fink C, Bork U, Stange A, Jäger D, Luntz SP, Englert S, Rossion I, Koch M, Büchler MW, Kieser M, Weitz J; SYNCHRONOUS trial group. Rahbari NN, et al. Among authors: stange a. BMC Cancer. 2012 Apr 5;12:142. doi: 10.1186/1471-2407-12-142. BMC Cancer. 2012. PMID: 22480173 Free PMC article. Clinical Trial.
63 results